Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
255
-
Total 13F shares, excl. options
-
168M
-
Shares change
-
-4.74M
-
Total reported value, excl. options
-
$1.26B
-
Value change
-
-$35.9M
-
Put/Call ratio
-
1.36
-
Number of buys
-
101
-
Number of sells
-
-121
-
Price
-
$7.52
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2024
305 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2024.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 255 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 168M shares
of 210M outstanding shares and own 79.97% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (22.1M shares), VANGUARD GROUP INC (21.9M shares), Avoro Capital Advisors LLC (11.9M shares), Kynam Capital Management, LP (9.09M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (8.14M shares), STATE STREET CORP (7.5M shares), ALKEON CAPITAL MANAGEMENT LLC (7.09M shares), GEODE CAPITAL MANAGEMENT, LLC (4.82M shares), RP Management, LLC (3.85M shares), and Nuveen Asset Management, LLC (3.42M shares).
This table shows the top 255 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.